Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients
Abstract
Objective: To identify novel polymorphisms in the solute carrier SLC22A16 gene and determine their influence on the pharmacokinetics of doxorubicin and doxorubicinol in Asian breast cancer patients. Methods:SLC22A16 coding regions were screened in a total of 400 healthy subjects belonging to three distinct Asian ethnic groups (Chinese [n = 100], Malays [n = 100] and Indians [n = 100]) and in the Caucasian population (n = 100). Pharmacokinetic parameters of doxorubicin and doxorubicinol were estimated in Asian breast cancer patients undergoing adjuvant chemotherapy to investigate genotype–phenotype correlations. Results: Four novel polymorphisms (c.146A>G [exon 2], c.312T>C, c.755T>C [exon 4] and c.1226T>C [exon 5]) were identified. The genotypic frequency of the homozygous c.146GG polymorphism was approximately twofold higher in the healthy Chinese (13%) & Malay (18%) populations compared with the Indian (7%) and Caucasian (9%) populations. The genotypic frequency of the c.1226T>C polymorphism was observed to be significantly higher among the Caucasian (11%) and Indian (8%) study subjects compared with the Chinese (1%) and Malay (1%) ethnic groups (p < 0.005 in each case). Breast cancer patients harboring the 146GG genotype showed a trend towards higher exposure levels to doxorubicin (AUC0–∞/dose/body surface area [BSA] [hm-5]: 21.6; range: 18.8–27.7) compared with patients with either the reference genotype (AUC0–∞/dose/BSA[hm-5]: 17.4; range: 8.2–26.3, p = 0.066) or heterozygotes (AUC0–∞/dose/BSA[hm-5]: 15.4; range: 6.2–38.0, p = 0.055). The exposure levels of doxorubicinol were also higher in patients harboring the variant 146GG genotype (AUC0–∞/dose/BSA[hm-5]: 13.3; range: 8.8–21.7) when compared with patients harboring the reference genotype (AUC0–∞/dose/BSA[hm-5]): 9.8; range: 6.1–24.3, p = 0.137) or heterozygotes (AUC0–∞/dose/BSA[hm-5]: 8.98; range: 3.7–20.6, p = 0.047). Conclusion: Among the four novel SLC22A16 polymorphisms identified, the c.146A>G and c.1226T>C polymorphisms exhibited interethnic variations in allele and genotype frequencies. This exploratory study suggests that the c.146A>G variation could contribute to the variations in the pharmacokinetics of doxorubicin and doxorubicinol in Asian cancer patients. Further in vitro studies are required to determine the functional impact of these novel polymorphisms on doxorubicin pharmacokinetics in cancer patients.
Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
Bibliography
- 1 Venter JC, Adams MD, Myers EW et al.: The sequence of the human genome. Science291,1304–1351 (2001).
- 2 Lander ES, Linton LM, Birren B et al.: Initial sequencing and analysis of the human genome. Nature409,860–921 (2001).
- 3 Lennernas H: Intestinal drug absorbtion and bioavailability: beyond involvement of single transport function. J. Pharm. Pharmacol.55,429–433 (2003).
- 4 Lee W, Kim RB: Transporters and renal drug elimination. Ann. Rev. Pharmacol. Toxicol.44,137–166 (2004).
- 5 Chandra P, Brouwer KL: The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res.21,719–735 (2004).
- 6 Lee G, Dallas S, Hong M et al.: Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol. Rev.53,569–595 (2001).
- 7 Ulrike S, Wolfgang W: Reversal of ABC transporter-dependent multidrug resistance in cancer: a realistic option? Am. J. Cancer5,285–297 (2006).
- 8 Andreadis C, Gimotty PA, Wahl P et al.: Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood109(8),3409–3416 (2007).
- 9 Xiang X, Rao SJ, Li HH et al.: Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet. Genomics16,683–691 (2006).
- 10 Cui Y, Konig J, Leier I et al.: Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J. Biol. Chem.276,9626–9630 (2001).
- 11 Thomas J, Wang L, Clark RE et al.: Active transport of imatinib into and out of cells: implications for drug resistance. Blood104,3739–3745 (2004).
- 12 Kivisto KT, Niemi M: Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm. Res.24,239–247 (2007).
- 13 Gong S, Lu X, Xu Y et al.: Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. Exp. Hematol.30,1162–1169 (2002).
- 14 Enomoto A, Wempe MF, Tsuchida H et al.: Molecular identification of a novel carnitine transporter specific to human testis. Insights into the mechanism of carnitine recognition. J. Biol. Chem.277,36262–36271 (2002).
- 15 Eraly SA, Nigam SK: Novel human cDNAs homologous to Drosophila Orct and mammalian carnitine transporters. Biochem. Biophys. Res. Commun.297,1159–1166 (2002).
- 16 Okabe M, Unno M, Harigae H et al.: Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem. Biophys. Res. Commun.333,754–762 (2005).• The authors demonstrate that the SLC22A16 transporter mediates the uptake of doxorubicin and determines doxorubicin transport kinetic parameters in in vitro experiments.
- 17 Treem WR, Stanley CA, Finegold DN et al.: Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle, and fibroblasts. N. Engl. J. Med.319,1331–1336 (1988).
- 18 Waber LJ, Valle D, Neill C et al.: Carnitine deficiency presenting as familial cardiomyopathy: a treatable defect in carnitine transport. J. Pediatr.101,700–705 (1982).
- 19 Chapoy PR, Angelini C, Brown WJ et al.: Systemic carnitine deficiency – a treatable inherited lipid-storage disease presenting as Reye’s syndrome. N. Engl. J. Med.303,1389–1394 (1980).
- 20 Elisaf M, Bairaktari E, Katopodis K et al.: Effect of l-carnitine supplementation on lipid parameters in hemodialysis patients. Am. J. Nephrol.18,416–421 (1998).
- 21 Speth PA, van Hoesel QG, Haanen C: Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinet.15,5–31 (1988).
- 22 Kirchheiner J, Fuhr U, Brockmoller J: Pharmacogenetics based therapeutic recommendations – ready for clinical practice? Nat. Rev. Drug Discov.4,639–647 (2005).
- 23 Koepsell H, Endou H: The SLC22 drug transporter family. Pflugers Arch.447,666–676 (2004).• Provides an overview on the classification and function of the solute carrier family 22 transporters.
- 24 Popp C, Gorboulev V, Muller TD et al.: Amino acids critical for substrate affinity of rat organic cation transporter 1 line the substrate binding region in a model derived from the tertiary structure of lactose permease. Mol. Pharmacol.67,1600–1611 (2005).
- 25 Feng B, Dresser MJ, Shu Y, Johns SJ, Giacomini KM: Arginine 454 and lysine 370 are essential for the anion specificity of the organic anion transporter, rOAT3. Biochemistry40,5511–5520 (2001)
- 26 Wu H, Hait WN, Yang J: Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res.63,1515–1519 (2003).
- 27 Frank NY, Margaryan A, Huang Y et al.: ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res.65,4320–4333 (2005).
- 28 Pratt S, Shepard RL, Kandasamy RA et al.: The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol. Cancer Ther.5,855–863 (2005).
- 29 Wang X, Furukawa T, Nitanda T et al.: Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol. Pharmacol.63,65–72 (2003).
- 30 Singhal SS, Singhal J, Nair MP et al.: Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int. J. Oncol.30,717–725 (2007).
